Skip to content

US · SOLV · MEDICAL - INSTRUMENTS & SUPPLIES

Solventum Corporation (SOLV) intrinsic value and stock valuation

$84.50as of 2026-11-21 · Mkt cap 15.15B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Solventum Corporation DCF and intrinsic value

InvestorsCraft values SOLV with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from SOLV’s statements →

Solventum Corporation Graham Number

Graham Number: $76.37d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Eagan, MN 55121 solventum.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$8.33B+2.7% 5y CAGRd
20202025
Net income
$1.56B+6.5% 5y CAGRd
20202025
Free cash flow
-$-10M
20202025
Total equity
$5.05B
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$8.33B$8.25B$8.2B$8.13B$8.17B
Operating income$2.18B$1.04B$1.69B$1.69B$1.88B
Net income$1.56B$479M$1.35B$1.34B$1.46B
EPSd$8.88M$2.76M$7.79M$7.79M$8.47M
Operating cash flow$369M$1.19B$1.92B$1.68B$2.2B
Capital expenditure-$-379M-$-380M-$-290M-$-251M-$-277M
Free cash flow-$-10M$805M$1.63B$1.43B$1.93B
Total assets$14.3B$14.5B$13.9B$13.6B$14.1B
Total debt$5.04B$8.01B$8.3B$95M$112M
Net debt$4.16B$7.25B$8.11B$34M$21M
Total equity$5.05B$2.96B$11.7B$11.7B$12.1B
Cash and short-term investments$878M$762M$194M$61M$91M
Income statement
20252024202320222021
Revenue$8.33B$8.25B$8.2B$8.13B$8.17B
Cost of revenue$3.87B$3.66B$3.5B$3.44B$3.25B
Gross profit$4.45B$4.59B$4.69B$4.7B$4.92B
Research and development expenses$739M$775M$758M$767M$766M
Selling, general and administrative expenses$3.08B$2.78B$2.24B$2.24B$2.28B
Other expenses-$-1.55B$0.00$0.00$0.00$0.00
Operating expenses$2.27B$3.56B$3B$3B$3.04B
Cost and expenses$6.14B$7.22B$6.51B$6.44B$6.29B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$347M$367M$0.00$0.00$0.00
Depreciation and amortization$489M$555M$561M$578M$597M
Ebitda$2.55B$1.53B$2.23B$2.27B$2.48B
Operating income$2.18B$1.04B$1.69B$1.69B$1.88B
Total other income/expenses, net-$-468M-$-431M-$-25M-$-1M$3M
Income before tax$1.71B$605M$1.67B$1.69B$1.88B
Income tax expense$157M$127M$321M$349M$422M
Net income$1.56B$479M$1.35B$1.34B$1.46B
Weighted average shares outstanding$174.1M$173.2M$172.7M$172.5M$172.5M
Weighted average diluted shares outstanding$175.3M$173.7M$172.7M$172.5M$172.5M
Balance sheet
20252024202320222021
Cash and short-term investments$878M$762M$194M$61M$91M
Net receivables$1.03B$1.23B$1.31B$1.17B$1.18B
Inventory$1.07B$965M$857M$873M$813M
Total current assets$3.86B$3.25B$2.52B$2.23B$2.19B
Property, plant and equipment, net$1.33B$1.62B$1.46B$1.32B$1.31B
Goodwill and intangible assets$8.3B$8.92B$9.44B$9.69B$10.3B
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$10.4B$11.2B$11.4B$11.4B$11.9B
Total assets$14.3B$14.5B$13.9B$13.6B$14.1B
Accounts payable$687M$618M$477M$348M$320M
Short-term debt$0.00$200M$0.00$27M$29M
Deferred revenue$621M$572M$574M$559M$0.00
Total current liabilities$3.14B$2.7B$1.73B$1.31B$1.41B
Long-term debt$5.04B$7.81B$8.3B$68M$83M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$6.11B$8.8B$549M$541M$610M
Capital lease obligations$0.00$0.00$0.00$68M$112M
Total liabilities$9.25B$11.5B$2.28B$1.85B$2.02B
Common stock$2M$2M$0.00$0.00$0.00
Retained earnings$1.8B$242M$0.00$0.00$0.00
Accumulated other comprehensive income (loss)-$-625M-$-1.06B-$-337M-$-497M-$-200M
Total equity$5.05B$2.96B$11.7B$11.7B$12.1B
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$5.04B$8.01B$8.3B$95M$112M
Net debt$4.16B$7.25B$8.11B$34M$21M
Cash flow statement
20252024202320222021
Net income$1.56B$479M$1.35B$1.34B$1.46B
Depreciation and amortization$489M$555M$561M$578M$597M
Stock-based compensation$161M$112M$39M$37M$38M
Change in working capital-$-119M$160M$126M-$-202M$67M
Accounts receivable$78M$276M-$-129M-$-32M-$-1M
Inventory-$-139M-$-132M$23M-$-82M-$-136M
Accounts payable$104M$266M$105M$25M$68M
Net cash provided by operating activities$369M$1.19B$1.92B$1.68B$2.2B
Investments in property, plant and equipment-$-379M-$-380M-$-290M-$-251M-$-277M
Acquisitions, net-$-696M$0.00$60M$0.00$0.00
Net cash used for investing activities$2.8B-$-380M-$-230M-$-253M-$-278M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-3.06B-$-240M-$-1.55B-$-1.46B-$-1.96B
Net change in cash$116M$568M$133M-$-30M-$-33M
Cash at end of period$878M$762M$194M$61M$91M
Operating cash flow$369M$1.19B$1.92B$1.68B$2.2B
Capital expenditure-$-379M-$-380M-$-290M-$-251M-$-277M
Free cash flow-$-10M$805M$1.63B$1.43B$1.93B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Solventum Corporation

        Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.

        CEO
        Bryan C. Hanson
        Employees
        20K
        Beta
        0.72

        Explore

        Frequently asked questions

        What is the intrinsic value of Solventum Corporation (SOLV)?

        Solventum Corporation (SOLV) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SOLV undervalued?

        SOLV trades at a price of $84.50 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.